Biosimilar ABP 654 Has Functional Similarity to Ustekinumab (Stelara ®)

Study finds the biosimilar ABP 654 and ustekinumab do not have clinical meaningful differences according to the step-wide totality-of-evidence approach and thus have similar psychochemical and biological properties.

Related Keywords

California ,United States ,China ,Chinese ,Greg Cantin ,Amgen ,Linkedin ,Cation Exchange High ,European Union ,Thousands Oak ,Exclusion High ,Performance Liquid Chromatography ,Light Scattering ,Cation Exchange High Performance Liquid ,Specificity Against Cytokines Related ,Gamma Receptor ,Antibody Dependent Cell Mediated Cytotoxicity ,Complement Dependent Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,